Trial Profile
A multicenter phaseII study of FOLFIRI as FOLFOX refractory second-line chemotherapy for metastatic colorectal cancer with reduced starting dose of irinotecan in patients with honozygous for UGT1A1: (FLIGHT2)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Sep 2018
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Fluorouracil; Folinic acid
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms FLIGHT2
- 15 Sep 2009 New trial record